The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
1/1000. Predicted molecular weight: 83 kDa.
Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.
Overexpressed in breast and colon cancer.
Involvement in disease
Note=A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is frequently found in all cases of endometrial stromal tumors, except in endometrial stromal sarcomas, where it is rarer.
Belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family. Contains 1 C2H2-type zinc finger.
Expressed at low levels in quiescent cells. Expression rises at the G1/S phase transition.
ChIP analysis using Mouse ES cells, labeling SUZ12 with ab195499 at 10 µg. ChIP was performed using 600 µg chromatin. IgG (10 μg) was used as negative IP control. The IP’d DNA was analysed by QPCR with specific primer sets for different positive and negative genes. The results are expressed as a % of input (the relative abundance of target DNA in the immunoprecipitates compared to the input DNA).
Western blot - Anti-SUZ12 antibody - N-terminal (ab195499)
Anti-SUZ12 antibody - ChIP Grade, purified (ab195499) at 1/1000 dilution (in TBS-Tween containing 5% skimmed milk) + HeLa nuclear extracts at 20 µg